Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

The Falcon Heavy rocket on the launchpad at the Kennedy Space Center in Florida during an earlier mission. SpaceX SpaceX’s triple-booster Falcon Heavy rocket was on track to launch before the end of ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

Learn how to design and craft your own custom laser-cut sign using the Creality Falcon A1. This step-by-step laser tutorial will guide you through the entire process, from setup to the perfect ...

Falcons are a class of birds best known for their speed, vision and hunting prowess. Here’s the story of perhaps the most impressive falcon of all. There are over 35 recognized species of falcons, all ...

(L-R) Willy Falcon and Ozzie Areu Courtesy A.R.E.U. EXCLUSIVE: Cuban-American drug kingpin Willy Falcon is finally poised to tell the story of how he built the billion-dollar cocaine empire Los ...

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) turned out to be a conclusive failure, ...

Mover (Former F-16 Block 30 pilot) tries out Falcon BMS testing out the landing pattern and ILS system. Shah's 50-year prediction for future of Iran resurfaces amid protests An all-time classic Ole ...